The effect of SGLT-2i in reducing the cardiotoxicity of breast cancer patients with T2DM during chemotherapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048421

Enrollment

Unknown

Registered

2021-07-06

Start date

2021-07-22

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer with diabetes

Interventions

Experimental group:Anthracycline + SGLT-2i

Control group:Anthracyclines + Metformin

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: The pathological diagnosis of breast cancer requires anthracycline-based chemotherapy in women with a past or current diagnosis of T2DM.

Exclusion criteria

Exclusion criteria: 1. Aged 85 years; 2. Pregnant patients and lactating patients; 3. Systemic metastasis has been confirmed by imaging or pathology at the time of diagnosis; 4. Serious cardiovascular diseases such as heart failure and acute coronary syndrome have occurred before chemotherapy; 5. Severe renal insufficiency (eGFR<45 ml/min/1.73 m^2); 6. Other serious life-threatening conditions such as severe hepatic insufficiency.

Design outcomes

Primary

Measure	Time frame
Detection rate of arrhythmia;	—

Countries

China

Contacts

Public ContactChang Jing

Chongqing Medical University

1290082076@qq.com+86 13368128260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026